Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S in the transaction.Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of 2,500,000…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
